Market Cap 74.45M
Revenue (ttm) 7.01M
Net Income (ttm) -32.01M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -456.63%
Debt to Equity Ratio 0.00
Volume 18,000
Avg Vol 182,010
Day's Range N/A - N/A
Shares Out 30.64M
Stochastic %K 56%
Beta 0.57
Analysts Strong Sell
Price Target $4.50

Company Profile

InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery and other vascular diseases in Europe, Latin America, the Middle East, and the Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard neuroprotection system for transcarotid access and neuro protection, as w...

Industry: Medical Devices
Sector: Healthcare
Phone: 888 776 6804
Address:
6303 Waterford District Drive, Suite 215, Miami, United States
Threeways
Threeways Jul. 24 at 2:23 PM
$NSPR there is zero chance this gets bought out in the next year and about 2% chance in two years. It just doesn't make sense for it to happen within the next 2 years at minimum. No one should want that either. Theres more money to be made at a 500 million or a billion market cap compared to now
2 · Reply
zigsfrd
zigsfrd Jul. 24 at 1:48 PM
$NSPR I can't say I've ever owned a stock with such a limited downside but with massive upside potential that simply requires my patience, which is already stretched thin.
2 · Reply
LoyalShark
LoyalShark Jul. 24 at 1:36 PM
$NSPR Just a reminder.
1 · Reply
HOBOWITHASHOTGUN
HOBOWITHASHOTGUN Jul. 24 at 1:30 PM
$NSPR Is it time to start drinking the Kool-Aid?
0 · Reply
LoyalShark
LoyalShark Jul. 24 at 12:24 PM
$NSPR Putting on my Bullish hat. I mean.....how many times could I possibly be wrong! Its go time!!
2 · Reply
arcuy
arcuy Jul. 23 at 10:01 PM
0 · Reply
LoyalShark
LoyalShark Jul. 23 at 1:28 PM
$NSPR Know a few surgeons in the TCAR space. The CGuard EPS (as they all know it) has been especially interesting to the vascular guys that were on the fence. Usually a new product intro takes longer and takes more money than anyone ever dreamed. THIS has been on the market for so long I am hopeful the adoption goes faster than I am thinking. I am not sure there will be any bigger buyout bait in the medtech arena than if NSPR shows ANY signs of taking market share. First time the CGuard EPS looks like a threat to the existing landscape of stents when looking at marketshare...InspireMd will be bought out. No maker of stents in this world is going to go through the multiyear process to trt to compete with the results the CGuard has had. Im not really sure you can improve on the results actually. CGuard created a cliamte of diminishing returns for anyone looking to compete. Feel like I have been here before. ANd feel like I have been here 90 yrs.
3 · Reply
DocRosen
DocRosen Jul. 22 at 1:35 PM
$NSPR why does everyone on here have the same avatar? 🐐
3 · Reply
GiveHerTheDD
GiveHerTheDD Jul. 22 at 12:16 PM
$NSPR will release its second quarter 2025 financial results on Tuesday, August 5, 2025 at 8:30 am ET. Early in the week and premarket points to positive news 👀
0 · Reply
abdolfos
abdolfos Jul. 22 at 10:29 AM
$NSPR Shouldn't they have filled out form 13g with the exercise of the warrants?
1 · Reply
Latest News on NSPR
InspireMD to Announce Second Quarter 2025 Financial Results

Jul 22, 2025, 7:00 AM EDT - 4 days ago

InspireMD to Announce Second Quarter 2025 Financial Results


InspireMD, Inc. (NSPR) Q1 2025 Earnings Call Transcript

May 9, 2025, 12:07 PM EDT - 2 months ago

InspireMD, Inc. (NSPR) Q1 2025 Earnings Call Transcript


InspireMD Reports First Quarter 2025 Financial Results

May 9, 2025, 7:00 AM EDT - 2 months ago

InspireMD Reports First Quarter 2025 Financial Results


InspireMD to Announce First Quarter 2025 Financial Results

Apr 25, 2025, 9:00 AM EDT - 3 months ago

InspireMD to Announce First Quarter 2025 Financial Results


InspireMD, Inc. (NSPR) Q4 2024 Earnings Call Transcript

Mar 12, 2025, 1:53 PM EDT - 4 months ago

InspireMD, Inc. (NSPR) Q4 2024 Earnings Call Transcript


InspireMD, Inc. (NSPR) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 10:20 AM EST - 9 months ago

InspireMD, Inc. (NSPR) Q3 2024 Earnings Call Transcript


InspireMD, Inc. (NSPR) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 8:58 AM EDT - 1 year ago

InspireMD, Inc. (NSPR) Q2 2024 Earnings Call Transcript


InspireMD Inc. (NSPR) Q1 2024 Earnings Call Transcript

May 14, 2024, 10:50 AM EDT - 1 year ago

InspireMD Inc. (NSPR) Q1 2024 Earnings Call Transcript


InspireMD Inc. (NSPR) Q4 2023 Earnings Call Transcript

Mar 6, 2024, 11:30 AM EST - 1 year ago

InspireMD Inc. (NSPR) Q4 2023 Earnings Call Transcript


InspireMD Inc. (NSPR) Q3 2023 Earnings Call Transcript

Nov 6, 2023, 11:09 AM EST - 1 year ago

InspireMD Inc. (NSPR) Q3 2023 Earnings Call Transcript


InspireMD Inc. (NSPR) Q2 2023 Earnings Call Transcript

Aug 8, 2023, 11:18 AM EDT - 2 years ago

InspireMD Inc. (NSPR) Q2 2023 Earnings Call Transcript


Threeways
Threeways Jul. 24 at 2:23 PM
$NSPR there is zero chance this gets bought out in the next year and about 2% chance in two years. It just doesn't make sense for it to happen within the next 2 years at minimum. No one should want that either. Theres more money to be made at a 500 million or a billion market cap compared to now
2 · Reply
zigsfrd
zigsfrd Jul. 24 at 1:48 PM
$NSPR I can't say I've ever owned a stock with such a limited downside but with massive upside potential that simply requires my patience, which is already stretched thin.
2 · Reply
LoyalShark
LoyalShark Jul. 24 at 1:36 PM
$NSPR Just a reminder.
1 · Reply
HOBOWITHASHOTGUN
HOBOWITHASHOTGUN Jul. 24 at 1:30 PM
$NSPR Is it time to start drinking the Kool-Aid?
0 · Reply
LoyalShark
LoyalShark Jul. 24 at 12:24 PM
$NSPR Putting on my Bullish hat. I mean.....how many times could I possibly be wrong! Its go time!!
2 · Reply
arcuy
arcuy Jul. 23 at 10:01 PM
0 · Reply
LoyalShark
LoyalShark Jul. 23 at 1:28 PM
$NSPR Know a few surgeons in the TCAR space. The CGuard EPS (as they all know it) has been especially interesting to the vascular guys that were on the fence. Usually a new product intro takes longer and takes more money than anyone ever dreamed. THIS has been on the market for so long I am hopeful the adoption goes faster than I am thinking. I am not sure there will be any bigger buyout bait in the medtech arena than if NSPR shows ANY signs of taking market share. First time the CGuard EPS looks like a threat to the existing landscape of stents when looking at marketshare...InspireMd will be bought out. No maker of stents in this world is going to go through the multiyear process to trt to compete with the results the CGuard has had. Im not really sure you can improve on the results actually. CGuard created a cliamte of diminishing returns for anyone looking to compete. Feel like I have been here before. ANd feel like I have been here 90 yrs.
3 · Reply
DocRosen
DocRosen Jul. 22 at 1:35 PM
$NSPR why does everyone on here have the same avatar? 🐐
3 · Reply
GiveHerTheDD
GiveHerTheDD Jul. 22 at 12:16 PM
$NSPR will release its second quarter 2025 financial results on Tuesday, August 5, 2025 at 8:30 am ET. Early in the week and premarket points to positive news 👀
0 · Reply
abdolfos
abdolfos Jul. 22 at 10:29 AM
$NSPR Shouldn't they have filled out form 13g with the exercise of the warrants?
1 · Reply
GiveHerTheDD
GiveHerTheDD Jul. 21 at 5:34 PM
$NSPR Investors and analysts want to see raw numbers. Just wait for Q3 earnings to show revenues increasing tenfold. Even Q2 earnings can show a big jump if they had shipments standing by for those final 2 weeks of the quarter when CGuard Prime got BOTH FDA approval and CE mark. I am incredibly hopeful that the carotid artery stenting world turns to CGuard for all future procedures. I mean - why would any doctor put an inferior stent into a patient? To further capitalize on the market, as revenues increase from 2025 to 2026, NSPR will soon get TCAR approval for CGuard Prime, in addition to the one of few peripherals to even conduct the procedure with SwitchGuard. What I think we have is a massive snowball slowly building up. I know FDA approval did not give returns, but that is also a speculative event. What is not speculative is when NSPR puts words into actions.
0 · Reply
HM135
HM135 Jul. 18 at 4:11 PM
$NSPR i mean any new volume and this thing is doing a moonshot
1 · Reply
abdolfos
abdolfos Jul. 18 at 9:27 AM
$NSPR https://www.linkedin.com/posts/inspiremd_snis2025-cguardprime-fdaapproved-activity-7351600404293423104-6yc6?utm_source=share&utm_medium=member_desktop&rcm=ACoAAA1sw9kBkryPFs0o2k6u5YO6aHtj0oIUPGQ
0 · Reply
LoyalShark
LoyalShark Jul. 18 at 12:56 AM
$NSPR I wake up everyday praying to see InspireMD fired Marvin Slosman and hired a real CEO .
0 · Reply
Ronnie5isAlive
Ronnie5isAlive Jul. 17 at 11:42 PM
$NSPR opportunity cost still hammering hard with this ultra long hold. I hope Starvin Marvin is cookin up a killer deal for a future buyout. #2.50
0 · Reply
DocRosen
DocRosen Jul. 17 at 8:20 PM
$NSPR good to see them spreading the word
0 · Reply
GiveHerTheDD
GiveHerTheDD Jul. 16 at 3:38 PM
$NSPR Q2 earnings will be in about 2-3 weeks and hopefully they shed some light on how revenues have and will change with CGuard Prime both CE marked and FDA approved. Less than 4k stents were sold last quarter and they reported under 2 mil in revenue. That number should be doubling at least 🤷‍♂️
1 · Reply
MrBugatti007
MrBugatti007 Jul. 15 at 3:48 PM
$NSPR news due any day
1 · Reply
HOBOWITHASHOTGUN
HOBOWITHASHOTGUN Jul. 15 at 3:06 PM
$NSPR So $CYCC makes a leadership change and look what happens... Hmmmmmm.
0 · Reply
Ronnie5isAlive
Ronnie5isAlive Jul. 15 at 1:21 PM
$NSPR Behold the bitter face of a deceased old miser clutching his NSPR stock certificate while the security finally rises as he gets lowered into the ground. Wall Street at its finest.
2 · Reply
LoyalShark
LoyalShark Jul. 15 at 12:57 PM
$NSPR Can Slosman get his shit together when it comes to the markets -- probably not.
0 · Reply
zigsfrd
zigsfrd Jul. 14 at 11:15 PM
$NSPR What these boys need to do is get their asses in gear and market our product to produce consistent cash flow. That more than anything else will attract attention to this company in the form of buyout interest or stock appreciation. We've been patient but need performance.
1 · Reply